Introduction

Biologic drugs such as monoclonal antibodies, recombinant proteins, gene therapies, and mRNA vaccines have become a cornerstone in modern medicine. These advanced therapies rely on efficient expression systems to achieve high yields and cost-effective production. Among these, Escherichia coli (E. coli) stands out as the most widely used prokaryotic host thanks to its rapid growth, clear genetic background, and scalable expression potential. It plays a vital role in the production of recombinant proteins, vaccines, enzymes, plasmid DNA, and therapeutic biomolecules.

However, while E. coli is an efficient production host, its own biological by-products—such as host cell proteins (HCPs) and host cell DNA (HCD)—pose safety and quality concerns. Regulatory agencies around the world emphasize stringent monitoring and removal of residual host cell DNA during drug development and manufacturing. Reliable residual DNA detection methods are essential to meet safety standards and ensure patient well-being.

Figure 1: Broad Applications of the E. coli Recombinant Expression System in Biopharmaceutical and Other Fields

Global Regulatory Standards for Residual DNA

International guidelines set strict limits on acceptable DNA residues in biologics, reflecting different administration routes and dosage forms.

• FDA (U.S.): residual DNA ≤ 10 ng per dose; for biologics, host cell DNA ≤ 100 pg per dose.
• European Pharmacopoeia: residual DNA ≤ 10 ng per dose.
• Chinese Pharmacopoeia (2025 Edition):
1. Biologics produced from cell substrates: residual DNA ≤ 100 pg/dose.
2. Vaccines from bacterial/fungal substrates: ≤ 10 ng/dose.
3. Mandatory use of qPCR (General Chapter 3407 Method III) for host cell DNA detection.

These updates clearly indicate that qPCR-based residual DNA detection kits are becoming the industry standard.

Table 1: Comparison of HCD Detection Requirements in 2025 vs 2020 Editions of the Chinese Pharmacopoeia

Hzymes’ Comprehensive E. coli Residual DNA Detection Solution

To address these needs, Hzymes Biotech provides a two-part solution designed for biologics quality assurance and compliance with global pharmacopoeia standards. Hzymes' E. coli Residual DNA Detection Kit (Catalog No.: HBP003503) and the accompanying Sample Pre-treatment Kit (Catalog No.: HBP003610), which adopt qPCR fluorescence probe technology and magnetic bead-based nucleic acid extraction, respectively, provide an accurate and efficient quality control solution for detecting E. coli residual DNA in biologics. These kits are applicable across all stages of biopharmaceutical development.

Figure 2: Manual/Automated Extraction + E. coli Residual DNA Detection Workflow

Applications Across the Biologics Workflow

Hzymes’ detection kits are versatile, supporting multiple stages of biologics development:

• Process Development & Optimization: monitor residual DNA during strain screening, fermentation, and purification.
• Raw Material Release: verify that raw materials such as media and buffers are free from E. coli contamination.
• In-process & Final Product Release: ensure consistent compliance before product batch release.

By integrating residual DNA detection into every step, manufacturers can strengthen process control and safeguard patient safety.

Key Features and Advantages

Hzymes’ E. coli residual DNA solution delivers multiple benefits:

1. Quantitative Accuracy
• Calibrated against the national DNA standard.
• Pharmacopoeia-compliant primer-probe sets for precise quantification.
2. Stable Results
• Validated across proteins, vaccines, antibody drugs, and plasmid DNA.
• Spike recovery rates consistently between 70–130%.
3. Ease of Use
• Manual and automated extraction options.
• Reduced hands-on time for improved efficiency.
4. High-Quality Service
• Tailored solutions to meet customer needs.
• Responsive technical support ensures smooth implementation.

Performance Data and Validation

Hzymes’ kits are rigorously validated with robust data:

Linearity Range

The product offers a wide linear range from 30 fg/μL to 300 pg/μL, with R² = 1.000 and an amplification efficiency of 98.22%. The coefficient of variation (CV) at all concentrations is less than 15%.

Figure 3: E. coli Standard Curve Amplification Plot

Accuracy

Hzymes' E. coli DNA standards are calibrated against the national DNA reference standard, with a purity of 100%. qPCR-determined concentrations show RSD <5% compared to the national standard. Primers and probes match pharmacopoeial sequences, precisely meeting regulatory expectations.

Figure 4: Electrophoresis of Hzymes E. coli DNA Standards vs National Standard

Table 2: qPCR Quantification Results of Hzymes E. coli DNA Standards vs National Standard

Spike Recovery Rate

Validated across multiple customers and diverse sample types, the kit is compatible with recombinant proteins, enzyme preparations, plasmid DNA, and other sample categories for E. coli HCD detection. The spike recovery rate remains consistently between 70% and 130%.

Figure 5: Spike Recovery Rates from Multiple Customers Using Different Sample Types

Limit of Quantification and Precision

The kit provides a consistent limit of quantification (LOQ) down to 30 fg/μL. Precision testing shows that results from different operators have a CV of less than 15%, ensuring high experimental credibility and reproducibility.

Figure 6: Amplification Curve at 30 fg/μL Limit of Quantification

Table 3: Intermediate Precision Results

Specificity

The product demonstrates high specificity, capable of specifically detecting E. coli DNA without cross-reactivity from other common host cell DNA sources.

Figure 7: Cross-Reactivity Test with Different Genomic DNAs

Stability

The kit maintains performance after accelerated thermal aging for 14 days at 37°C and after five freeze-thaw cycles, showing no loss in functionality. Storage and transportation are thus worry-free. Inter-lot consistency tests further demonstrate stable and uniform product performance.

Table 4: Stability under 37°C Heat Acceleration and Freeze-Thaw Conditions

Figure 8: Amplification Curves of Different Kit Lots

Why Choose Hzymes for Residual DNA Detection

Hzymes Biotech is a trusted partner for global biopharma companies. Choosing Hzymes means:

• Proven accuracy and sensitivity, validated by multiple customers worldwide.
• Full compliance with FDA, EMA, and Chinese Pharmacopoeia guidelines.
• Scalable workflows suitable for research, development, and large-scale manufacturing.
• Dependable partner in biologics quality control and residual DNA detection solutions.

Conclusion

Residual host cell DNA detection is a critical quality control step in biologics development, ensuring both regulatory compliance and patient safety. With global regulations tightening and qPCR becoming the standard method, having a reliable, accurate, and validated solution is essential.

Hzymes’ E. coli Residual DNA Detection Kit and Sample Pre-treatment Kit empower biopharma companies to achieve accurate, stable, and efficient DNA quantification—supporting everything from early process optimization to final product release.